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Joseph Pidala,1,3 Jongphil Kim,2,3 Teresa Field,1,3 Ali McBride,1,3
Mohamed Kharfan-Dabaja,1,3 Janelle Perkins,1,3 Hugo Fernandez,1,3
Lia Perez,1,3 Ernesto Ayala,1,3 Claudio Anasetti1,3Infliximab has demonstrated activity in the treatment of steroid-refractory acute graft-versus-host disease
(aGVHD). We aimed to confirm the effectiveness of infliximab as a salvage therapy for steroid-refractory
aGVHD. In a series of 52 patients, 71% of whom had grade III-IV aGVHD, only 15% achieved complete
remission (CR) with the use of infliximab alone as salvage therapy. CR of aGVHD differed according to overall
aGVHD grade at salvage (grade II, 5/15; grade III, 2/17; grade IV, 1/20; P5.03). Median overall survival (OS)
was only 1.7 months (95% confidence interval [CI]5 0.99 to 2.3 months). CR of aGVHD was significantly
associated with OS, with a hazard ratio of 8.4 for death in those without CR (95% CI5 3.6 to 19.6;
P\ .0001). This series demonstrates the limited activity of infliximab in patients with high-grade aGVHD.
Further work is needed to identify effective therapy for aGVHD.
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Acute graft-versus-host disease (aGVHD), an im-
portant source of treatment-related morbidity and
treatment-related mortality (TRM), occurs in up to
50% of recipients of matched related donor allogeneic
hematopoietic cell transplantation (HCT), with an
even higher rate in unrelated and mismatched HCT,
despite prophylaxis. Unfortunately, only 30% to
40% of patients treated with glucocorticoids will dem-
onstrate complete resolution of aGVHD. Steroid-re-
fractory disease portends a poor prognosis, with
published estimates of survival of only 5% to 30%
[1-11]. Various immunosuppressive agents have dem-
onstrated modest activity in this setting [12-31]. Inter-
est in infliximab for treating GVHD has been driven
by an understanding of the underlying etiologic role
of tumor necrosis factor alpha (TNF-a) in the patho-
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6/j.bbmt.2009.05.019Infliximab, a murine-human chimeric monoclonal
antibody (mAb) that binds the soluble subunit and the
membrane-bound precursor of TNF-a, has been ex-
amined in the treatment of steroid-refractory aGVHD
by several investigators. Several small case series have
suggested clinical activity of infliximab in this setting
[37-40]. Larger series also have demonstrated inflixi-
mab’s clinical activity, while drawing attention to
important infectious complications of its use in this
setting [41-43]. In the present study, we examined
the effectiveness of infliximab in the treatment of 52
patients with steroid-refractory aGVHD.METHODS
A nonconsecutive series of 52 patients treated at the
MoffittCancerCenter between 2001 and2008with ste-
roid-refractory aGVHD after allogeneic HCT (as de-
fined by grade progression within 3 days or failure to
achieve grade improvement within 5 days after the ini-
tiation of glucocorticoid therapy) was identified from
a total of 521 patients who underwent allogeneic
HCT during that period by retrospective chart review.
The study design was approved by the University of
South Florida’s Institutional Review Board. Starting
doses of systemic prednisone or methylprednisolone
ranged from 1 to 2 mg/kg. Data on aGVHD were
collected on the day of onset and weekly thereafter;
organ-specific grade andoverall gradewere assigned ac-
cording to the Glucksberg modified consensus criteria
Table 1. Baseline characteristics
Frequency Percent
Median age, years (range) 47.5 (18 to 69)
Disease category
SAA 1 2%
Acute lymphocytic leukemia 4 8%
Acute myelogenous leukemia/
myelodysplastic syndrome
22 42%
Chronic lymphocytic leukemia 4 8%
Chronic myelogenous leukemia 7 13%
Hodgkin disease 1 2%
Multiple myeloma 2 4%
Myeloproliferative disorder 3 6%
Non-Hodgkin lymphoma 8 15%
Remission status at time of HCT
Remission 20 38%
Not 32 62%
Stem cell source
Peripheral blood stem cells 50 96%
Bone marrow 2 4%
Donor relation
Related 21 40%
Unrelated 31 60%
HLA matching
10/10 36 69%
9/10 9 17%
8/10 1 2%
6/6 5 10%
5/6 1 2%
Recipient/donor sex
Female/female 7 13%
Female/male 14 27%
Male/female 16 31%
Male/male 15 29%
GVHD prophylaxis
CSA/MMF 1 2%
CSA/MTX 3 6%
TAC/MMF 12 23%
TAC/MTX 32 62%
TAC/MTX/visilizumab 2 4%
TAC/RAPA 2 4%
Donor/recipient CMV
Negative/negative 13 27%
Negative/positive 12 24%
Positive/negative 5 10%
Positive/positive 19 39%
Overall aGVHD grade at salvage
I 0 0%
Biol Blood Marrow Transplant 15:1116-1121, 2009 1117Infliximab for Refractory aGVHD[44]. Both classic aGVHD occurring within 100 days
after HCT and persistent or late aGVHD occurring
after 100 days, in the absence of features consistent
with cGVHD, were included in the sample. Data
collected also included the initial dose of gluco-
corticoids, duration of steroid exposure and overall
duration of immunosuppression, incidence and sever-
ity of chronic GVHD (cGVHD) [45], cytomegalovi-
rus (CMV) reactivation, primary disease relapse, and
death. Any additional immunosuppressive therapies
given after infliximab for ongoing refractory aGVHD
also were recorded.
Response rates for aGVHD resolution were calcu-
lated.Complete response (CR)was defined as complete
resolution of aGVHD after initiation of infliximab that
was sustained for at least 1month. Partial response (PR)
was defined as overall grade improvement of 1 grade or
more. Those who achieved a CR of aGVHD after
requiring additional salvage agents beyond infliximab
for persistent aGVHDwere designated nonresponders
to infliximab. Any recurrent aGVHD until date of
death or last follow-up was noted. Univariate logistic
regression analysis was performed to evaluate baseline
characteristics as predictors for CR with infliximab.
The cumulative incidences of primary disease relapse,
cGVHD, and CMV reactivation were calculated. The
Kaplan-Meiermethodwas used to estimate overall sur-
vival (OS) and relapse-free survival (RFS). Survival
endpoints were calculated using the starting date of
infliximab therapy as the baseline. The Cox propor-
tional hazardmodel was used to examine baseline char-
acteristics as predictors of OS. The Kaplan-Meier
method also was used to calculate the time to\20 mg
prednisone, time to liberation from prednisone, and
time to complete liberation from immune suppression.
Finally, any infectious complications of infliximab
treatment were noted.II 15 29%
III 17 33%
IV 20 38%
aGVHD organ involvement at salvage
Skin (total) 12 total 23% total
1 5 42%
2 4 33%
3 3 25%
4 0 0%
GI (total) 50 total 96% total
1 14 8%
2 9 18%
3 7 14%
4 20 40%
Liver (total) 6 total 12% total
1 2 33%
2 0 0%
3 3 50%
4 1 17%
SAA indicates severe aplastic anema; GVHD, graft-versus-host disease;
aGVHD, acute graft-versus-host disease; CsA, cyclosporine A; MMF,
mycophenolate mofetil; MTX, methotrexate; TAC, tacrolimus; RAPA, ;
CMV, cytomegalovirus; GI, gastrointestinal.RESULTS
This series of 52 patients with refractory aGVHD
(median time to onset of aGVHD from date of HCT,
84 days; range, 8 to 1658 days) was treated with inflix-
imab as salvage therapy after an initial 1 to 2 mg/kg
dose of glucocorticoids (median time from steroid ini-
tiation to infliximab initiation, 13 days; range, 1 to 100
days). No other salvage therapies were used before
infliximab. As shown in Table 1, the overall grade at
the time of aGVHD onset was generally advanced,
with grade III-IV constituting 71% of the total sample.
In addition, although a range of organ involvement is
represented in the sample, the preponderance (96%)
had gastrointestinal (GI) involvement at onset. Inflixi-
mab was dosed uniformly at 10 mg/kg; however, only
20 of 52 patients received all of the 4 planned doses
(12 patients received 1 dose, 9 received 2 doses, and
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Figure 1. Overall aGVHD grade in patients on weekly evaluation after
initiation of infliximab therapy.
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Figure 2. Overall survival.
Table 2. Cumulative incidence of patients experiencing
infectious complications after treatment with infliximab
Frequency Percent
Bacterial 37 71%
Viral 19 37%
Fungal 25 48%
1118 Biol Blood Marrow Transplant 15:1116-1121, 2009J. Pidala et al.11 received 3 doses). Reasons for giving fewer than 4
total doses included death from refractory aGVHD,
death from sepsis, or substitution of an alternative sal-
vage agent at the discretion of the treating physician.
In total, 15% of the patients in our sample
achieved a CR of aGVHD after treatment with inflix-
imab alone for steroid-refractory aGHVD at a median
of 6 days (range, 2 to 26 days) after initiation of inflix-
imab. Allowing for both those patients who had CR
to infliximab alone and those who ultimately achieved
CR after infliximab and additional salvage agents, the
composite CR rate was 35%. As shown in Figure 1,
we found a progressive increase in the number of liv-
ing patients who achieved a CR of aGVHD over 8
weeks after the initiation of infliximab. On univariate
analysis, the only baseline characteristic significantly
associated with the achievement of a CR with inflix-
imab was overall aGVHD grade at salvage (grade
II, 5/15; grade III, 2/17; grade IV, 1/20), with an
odds ratio of 5.7 for CR of aGVHD for grade I/II
versus III/IV (95% CI5 1.1 to 27.9; P5 .03). No
significant association was found between time of
infliximab administration and CR of aGVHD. One
patient experienced recurrent aGVHD of the liver
after an initial CR with infliximab, which developed
after discontinuation of tacrolimus in the setting of
thrombotic microangiopathy.
The OS realized in this series of patients with
steroid-refractory aGVHD was in keeping with the
poor outcomes reported with alternative salvage ther-
apies used in high-grade steroid-refractory aGVHD
(Figure 2), with a median OS from initiation of inflix-
imab treatment of 1.68 months (95% CI5 0.99 to 2.3
months). The OS was 5.0 months (95% CI5 2.3 to
17.6 months) in patients who achieved a CR with in-
fliximab alone, versus 1.3 months (95% CI5 0.9 to
2.1 months) in those who did not (P5 .046; log-rank
test) (Figure 3). Causes of death included refractory
aGVHD with or without sepsis (n5 25), sepsis
(n5 4), pneumonia/respiratory failure (n5 13),
relapse (n5 3), and hepatic veno occlusive disease
(n5 1). Examining baseline characteristics, a CR of
aGVHD with infliximab alone demonstrated border-
line significance, with a hazard ratio (HR) for death
of 0.44 (95% CI5 0.2 to 1.0; P5 .05); however, over-
all achievement of CR of aGVHD (including both
a CR with infliximab and a CR with infliximab and ad-
ditional salvage agents) was significantly associated
with OS. The HR for death in those without a CR ofaGVHD was 8.4 (95% CI5 3.6 to 19.6; P\ .0001).
No other baseline characteristic was significantly asso-
ciated with OS in this analysis.
Steroid-refractory aGVHD was associated with
a substantial burden of glucocorticoid exposure in
this sample. Of the 4 patients who received prednisone
of\20 mg, the median time to this event was 17.28
months. Only 2 patients were successfully weaned off
prednisone, at a median time of 17.35 months. Finally,
no patient achieved complete liberation from all im-
munosuppressant medications by time of death or
last follow-up.
CMV reactivation was monitored by weekly serum
CMV polymerase chain reaction (PCR) studies in all
patients; if CMV reactivation was detected, preemp-
tive therapy was initiated. The cumulative incidence
of CMV reactivation in this series was 54%. cGVHD
was seen in 15% of the patients; in this group, the
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Figure 3. Overall survival, those achieving a CR of aGVHD with infliximab versus those not achieving a CR.
Biol Blood Marrow Transplant 15:1116-1121, 2009 1119Infliximab for Refractory aGVHDmaximum score was 1 (mild) in 12%, 2 (moderate) in
63%, and 3 (severe) in 25%. The cumulative incidence
of primary disease relapse was 23%.
Although concurrently administered with cortico-
steroids and often additional immunosuppressive
agents, treatment of refractory aGVHD with inflixi-
mab resulted in a large burden of bacterial, viral (inva-
sive viral infections other than CMV reactivation), and
invasive fungal infectious complications (Table 2).DISCUSSION
Steroid-refractory aGVHD remains a significant
contributor to treatment-related morbidity and
TRM. Based on an understanding of the etiologic
role of TNF-a in the pathogenesis and maintenance
of aGVHD, infliximab has been developed as a salvage
therapy for refractory aGVHD. Although several
reports, case series, and larger series have documented
infliximab’s efficacy, treatment of advanced-grade
refractory aGVHD remains a challenge. In the present
study, we examined the outcomes of a series with
predominantly advanced-grade steroid-refractory
aGVHD of the GI tract to further elucidate the benefit
of infliximab therapy in this setting.
In this analysis, a CR rate of 15%was achieved with
infliximab alone in steroid-refractory aGVHD. All
baseline characteristics were examined as predictors of
CR of aGVHD with infliximab, and only the overall
aGVHD grade at salvage was found to reach statistical
significance. This effect of overall aGVHD grade on
the likelihood of a CR of aGVHD is in keeping with
trends reported in the literature. Couriel et al. [41] re-
ported a CR rate of 62% in a series of 21 patients who
received infliximab 10 mg/kg in several weekly doses
as the sole salvage therapy in refractory aGVHD; how-
ever, only 4of the 21patients in this series hadgrade III-IV aGVHD. Conversely, Patriarca et al. [42] reported
aCR rate of 19% in a series of 32 patientswithmore ad-
vanced aGVHD (grade II, 12%; grade III, 25%; grade
IV, 63%). In terms of predictors of aGVHD response,
Patriarca et al. found age\35 years, GI involvement,
and time fromHCTto infliximab initiation tobe signif-
icant predictors of response to infliximab. Our analysis
did not support these variables as significant predictors
of response, but our conclusions are necessarily limited
here because of the overrepresentation of GI involve-
ment in our series. Finally, the number of infliximab
doses received was not a significant predictor of
aGVHD response or OS in our analysis. Only 38% of
our patients received 4 doses (median, 3; range, 1 to
4), whereas in the study of Couriel et al. [41], 71% of
the patients received 4 doses (median, 4; range, 2 to
9), and in the study of Patriarca et al. [42], a median of
3 doses (range, 2 to 8) was delivered.
The long-term outcome of patients with steroid-
refractory aGVHD in our series was poor, with a me-
dian OS from time of infliximab treatment of 1.68
months (95%CI5 1.0 to 2.3), but nonetheless consis-
tent with reported OS in advanced-grade, steroid-re-
fractory aGVHD using other salvage therapies.
Major mortality factors here included refractory
aGVHD, sepsis, pneumonia/respiratory failure, and
primary disease relapse. Importantly, a CR of aGVHD
was a significant predictor of OS. The impact of a CR
of aGVHD on OS also was suggested by the study of
Patriarca et al. [42], where the OS at a median of 449
days after infliximab treatment was 68% in those
with responsive disease, whereas all of the unrespon-
sive patients died of refractory aGVHD by a median
of 43 days after onset. Conversely, Couriel et al. [41]
reported an OS of 38% at a median follow-up of 21
months, along with a median survival after HCT of
8.7 months. Long-term survival in steroid-refractory
aGVHD remains elusive for most patients.
1120 Biol Blood Marrow Transplant 15:1116-1121, 2009J. Pidala et al.In the present study, infliximab administered along
with high-dose glucocorticoids and often additional
immunosuppressive agents led to a number of infec-
tious complications despite the administration of stan-
dard infectious prophylaxis in all patients. These
results are comparable to those reported by Couriel
et al. [41] (bacterial infection, 81%; viral infection [in-
cluding CMV reactivation], 67%; fungal infection,
48%). Marty et al. [43] also have reported that inflixi-
mab is a significant risk factor for noncandidal invasive
fungal infections in severe aGVHD, with an HR of
13.6 (95% CI5 2.29 to 80.2; P5 .004). Treatment
of steroid-refractory aGVHD mandates cautious sur-
veillance for and prophylaxis against infectious com-
plications.
Overall, our results demonstrate the limited com-
plete remission of advanced-grade steroid-refractory
aGVHD induced by infliximab. Given that preclinical
data demonstrates a mechanistic role of TNF-a in
aGVHD development and maintenance, and that ele-
vated levels of TNF-a have been found in those
patients with aGVHD, there is a clear rationale for
pursuing anti-TNF therapy for aGVHD treatment
[32-36]. Although the reasons for infliximab’s limited
utility in this series of advanced-grade steroid-refrac-
tory aGVHD are not known, possible explanations
could include the role of other inflammatory cytokines
or other effector mechanisms involved in aGVHD
because of the advanced stage of the syndrome, or irre-
versible tissue injury that was no longer salvageable.
Further work remains to be done to identify effective
prophylaxis against and primary therapy for aGVHD.ACKNOWLEDGMENTS
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